James P. Allison, Ph.D.

Peer-Reviewed Articles

1. Chaib M, Aminu M, Herbrich S, Arabi M, Xuan Y, Basi A, Casasent A, Macaluso MD, Hu KH, Gubin M, Chen X, Mancuso JJ, Basu S, Jindal S, Burks J, Watowich S, Wu J, Allison JP, Sharma P. Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade. bioRxiv, 2025. e-Pub 2025. PMID: 41509466.
2. Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Nikpoor AR, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tallon de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Goepfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature 646(8084):462-473, 2025. e-Pub 2025. PMID: 40836096.
3. Mok, S, Liu, H, Çobanoğlu, DA, Anang, NA, Mancuso, JJ, Wherry, EJ, Allison, JP. Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1. Proceedings of the National Academy of Sciences of the United States of America 122(2), 2025. e-Pub 2025. PMID: 39786926.
4. Castro-Pando, S, Howell, RM, Li, L, Mascaro, M, Faraoni, E, Le Roux, O, Romanin, D, Tahan, V, Riquelme Sanchez, EM, Zhang, Y, Kolls, JK, Allison, JP, Lozano, G, Moghaddam, SM, McAllister, F. Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunology Research 12(9):1170-1183, 2024. e-Pub 2024. PMID: 38842383.
5. Sultan, H, Takeuchi, Y, Ward, JP, Sharma, N, Liu, TT, Sukhov, V, Firulyova, M, Song, Y, Ameh, S, Brioschi, S, Khantakova, D, Arthur, CD, White, JM, Kohlmiller, H, Salazar, AM, Burns, R, Costa, HA, Moynihan, KD, Yeung, YA, Djuretic, I, Schumacher, TN, Sheehan, KC, Colonna, M, Allison, JP, Murphy, KM, Artyomov, MN, Schreiber, RD. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature 632(8023):182-191, 2024. e-Pub 2024. PMID: 39048822.
6. Siddiqui, BA, Palaskas, NL, Basu, S, Dai, Y, He, Z, Yadav, SS, Allison, JP, Sheth, RA, Tummala, S, Buja, LM, Bhattacharjee, M, Iliescu, C, Rawther-Karedath, A, Deswal, A, Wang, L, Sharma, P, Subudhi, SK. Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunology Research 12(8):964-987, 2024. e-Pub 2024. PMID: 38768394.
7. Aparicio, A, Tidwell, RS, Yadav, SS, Chen, JS, Zhang, M, Liu, J, Guo, S, Pilie, PG, Yu, Y, Song, X, Vundavilli, H, Jindal, S, Zhu, K, Viscuse, PV, Lebenthal, J, Hahn, AW, Soundararajan, R, Corn, P, Zurita-Saavedra, A, Subudhi, SK, Zhang, J, Wang, W, Huff, C, Troncoso, P, Allison, JP, Sharma, P, Logothetis, CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
8. Mok, S, Çobanoğlu, DA, Liu, H, Mancuso, JJ, Allison, JP. Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America 121(27), 2024. e-Pub 2024. PMID: 38923991.
9. Sharma N, Fan X, Atolagbe OT, Ge Z, Dao KN, Sharma P, Allison JP. ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. J Exp Med 221(4):e20231263, 2024. e-Pub 2024. PMID: 38517331.
10. Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
11. Baruch EN, Nagarajan P, Gleber-Netto FO, Rao X, Xie T, Akhter S, Adewale A, Shajedul I, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunaratne P, Goepfert RP, Khushalani N, Wang J, Watowich S, Calin GA, Migden MR, Vermeer P, D'Silva N, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo J, Myers JN, Gross ND, Amit M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq, 2023. e-Pub 2023. PMID: 37503252.
12. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
13. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
14. Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 220(2):e20221333, 2023. e-Pub 2023. PMID: 36367776.
15. Amaria RN, Postow M, Burton EM, Tezlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
16. Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature 611(7937):818-826, 2022. e-Pub 2022. PMID: 36385524.
17. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
18. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707.
19. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
20. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
21. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
22. Wei SC, Mancuso JJ, Daver N, Allison JP. Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. Blood Cancer Discov 2(6):551-554, 2021. e-Pub 2021. PMID: 35015675.
23. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
24. Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10):e002919, 2021. e-Pub 2021. PMID: 34663638.
25. Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
26. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
27. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27(8):1432-1441, 2021. e-Pub 2021. PMID: 34239137.
28. Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med 218(7):e20201811, 2021. e-Pub 2021. PMID: 33974041.
29. Demetri GD, Luke JJ, Hollebecque A, Powderly JD, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher A, Villalobos VM. First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res 27(13):3556-3566, 2021. e-Pub 2021. PMID: 33820780.
30. Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer 9(5):e002254, 2021. e-Pub 2021. PMID: 33986125.
31. Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci 1489(1):30-47, 2021. e-Pub 2021. PMID: 33184911.
32. Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li Y, Atolagbe OT, Rao X, Zhao Y, Wang J, Ehrlich LIR, Sharma P, Salem JE, Balko JM, Moslehi JJ, Allison JP. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov 11(3):614-625, 2021. e-Pub 2021. PMID: 33257470.
33. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
34. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
35. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, Leveille JM, Brunner MR, Holden KW, Hopkins NS, Harris AM, Kumpati J, Whitt MA, Lee JJ, Ostrosky-Zeichner LL, Papanna R, LeBleu VS, Allison JP, Kalluri R. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunity. JCI Insight 5(18), 2020. e-Pub 2020. PMID: 32796155.
36. Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12(548), 2020. e-Pub 2020. PMID: 32554706.
37. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. e-Pub 2020. PMID: 31755915.
38. Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839, 2020. e-Pub 2020. PMID: 32296058.
39. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
40. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 20(2):75-76, 2020. e-Pub 2020. PMID: 31925406.
41. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
42. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2020. PMID: 31873309.
43. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
44. Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer 7(1):351, 2019. e-Pub 2019. PMID: 31843013.
45. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
46. Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A 116(45):22699-22709, 2019. e-Pub 2019. PMID: 31636208.
47. Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Scutti JB, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P. Characterization and comparison of GITR expression in solid tumors. Clin Cancer Res 25(21):6501-6510, 2019. e-Pub 2019. PMID: 31358539.
48. Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances adoptive T-cell therapy efficacy in an ICOS mediated manner. Cancer Immunol Res 7(11):1803-1812, 2019. e-Pub 2019. PMID: 31466995.
49. Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246-22251, 2019. e-Pub 2019. PMID: 31611368.
50. Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, van den Brink M, Dong C, Huang S, Zang X, Allison JP, Zeiser R, Blazar BR. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight 4(19), 2019. e-Pub 2019. PMID: 31578305.
51. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
52. Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res 7(9):1390-1395, 2019. e-Pub 2019. PMID: 31289040.
53. Sharma N, Vacher J, Allison JP. TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proc Natl Acad Sci U S A 116(21):10453-10462, 2019. e-Pub 2019. PMID: 31076558.
54. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 2019. e-Pub 2019. PMID: 30500073.
55. Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity 50(4):1084-1098.e10, 2019. e-Pub 2019. PMID: 30926234.
56. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2019. PMID: 30409776.
57. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin Cancer Res 25(4):1233-1238, 2019. e-Pub 2019. PMID: 30054281.
58. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019. PMID: 30635425.
59. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. Am Soc Clin Oncol Educ Book 39:147-164, 2019. e-Pub 2019. PMID: 31099674.
60. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188, 2019. e-Pub 2019. PMID: 30479380.
61. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1942, 2018. e-Pub 2018. PMID: 30361511.
62. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. PMID: 30420754.
63. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 2018. e-Pub 2018. PMID: 30361510.
64. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
65. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-8, 2018. e-Pub 2018. PMID: 29905573.
66. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59(4):790-802, 2018. e-Pub 2018. PMID: 28679300.
67. Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL, Vence LM, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24(5):1011-8, 2018. e-Pub 2018. PMID: 29246938.
68. Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res 6(2):189-200, 2018. e-Pub 2018. PMID: 29339377.
69. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-93, 2018. e-Pub 2018. PMID: 29361468.
70. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
71. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov 7(10):1088-97, 2017. e-Pub 2017. PMID: 28733428.
72. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-33.e17, 2017. e-Pub 2017. PMID: 28803728.
73. Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8(1):451, 2017. e-Pub 2017. PMID: 28878208.
74. Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. J Immunol 199(3):974-81, 2017. e-Pub 2017. PMID: 28646041.
75. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-5, 2017. e-Pub 2017. PMID: 28346412.
76. Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, Kalluri R. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 8:15095, 2017. e-Pub 2017. PMID: 28447602.
77. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-53, 2017. e-Pub 2017. PMID: 28223062.
78. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
79. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839-50, 2017. e-Pub 2017. PMID: 27821490.
80. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 8:14340, 2017. e-Pub 2017. PMID: 28194010.
81. Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic melanoma patient had a complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol Res 5(2):100-5, 2017. e-Pub 2017. PMID: 28062513.
82. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35, 2017. e-Pub 2017. PMID: 28428884.
83. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
84. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res 22(23):5729-37, 2016. e-Pub 2016. PMID: 27566765.
85. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-24, 2016. e-Pub 2016. PMID: 27698113.
86. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167(2):397-404.e9, 2016. e-Pub 2016. PMID: 27667683.
87. Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res 4(10):835-44, 2016. e-Pub 2016. PMID: 27587469.
88. Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol 9(1):81, 2016. e-Pub 2016. PMID: 27595932.
89. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7:12632, 2016. e-Pub 2016. PMID: 27572267.
90. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun 7:12335, 2016. e-Pub 2016. PMID: 27498556.
91. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
92. Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS promotes the function of CD4+ effector T cells during anti-OX40-mediated tumor rejection. Cancer Res 76(13):3684-9, 2016. e-Pub 2016. PMID: 27197182.
93. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
94. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces Immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 28(6):831-3, 2015. e-Pub 2015. PMID: 28843279.
95. Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep 13(2):412-24, 2015. e-Pub 2015. PMID: 26411680.
96. Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A 112(38):E5290-9, 2015. e-Pub 2015. PMID: 26351680.
97. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, Nischal H, Allison JP, Zeisberg M, Kalluri R. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 21(9):998-1009, 2015. e-Pub 2015. PMID: 26236991.
98. Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, Savage PA, van den Brink MR, Allison JP. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res 3(8):849-54, 2015. e-Pub 2015. PMID: 26122284.
99. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 2015. e-Pub 2015. PMID: 26069186.
100. Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknecht E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, Mak TW, van den Brink M, Zeiser R, Blazar BR. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood 125(21):3335-46, 2015. e-Pub 2015. PMID: 25814530.
101. Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol 194(5):2089-98, 2015. e-Pub 2015. PMID: 25624453.
102. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25(3):399-400, 2015. e-Pub 2015. PMID: 25732764.
103. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25(2):208-24, 2015. e-Pub 2015. PMID: 25582080.
104. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577-81, 2014. e-Pub 2014. PMID: 25428507.
105. Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res 2(10):970-80, 2014. e-Pub 2014. PMID: 25038199.
106. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719-34, 2014. e-Pub 2014. PMID: 24856586.
107. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211(4):715-25, 2014. e-Pub 2014. PMID: 24687957.
108. Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, Waldmann TA, Steel JC. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer. Gene Ther 21(4):393-401, 2014. e-Pub 2014. PMID: 24572789.
109. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32, 2014. e-Pub 2014. PMID: 24598590.
110. Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res 19(22):6112-25, 2013. e-Pub 2013. PMID: 24081977.
111. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4):229-34, 2013. e-Pub 2013. PMID: 24777852.
112. Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 1(4):235-44, 2013. e-Pub 2013. PMID: 24396833.
113. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695-710, 2013. e-Pub 2013. PMID: 23897981.
114. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210(7):1389-402, 2013. e-Pub 2013. PMID: 23752227.
115. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210(4):743-55, 2013. e-Pub 2013. PMID: 23547098.
116. Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP, Socci ND, Savage PA. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339(6124):1219-24, 2013. e-Pub 2013. PMID: 23471412.
117. Corse E, Gottschalk RA, Park JS, Sepulveda MA, Loke P, Sullivan TJ, Johnson LK, Allison JP. Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. J Immunol 190(2):526-30, 2013. e-Pub 2013. PMID: 23248264.
118. Lee JS, Scandiuzzi L, Ray A, Wei J, Hofmeyer KA, Abadi YM, Loke P, Lin J, Yuan J, Serreze DV, Allison JP, Zang X. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol 189(8):4165-74, 2012. e-Pub 2012. PMID: 22972920.
119. Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics 9(4):827-43, 2012. e-Pub 2012. PMID: 22996231.
120. Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 189(3):1123-7, 2012. e-Pub 2012. PMID: 22753941.
121. Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol 188(12):6156-64, 2012. e-Pub 2012. PMID: 22593619.
122. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A 109(16):6187-92, 2012. e-Pub 2012. PMID: 22474386.
123. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925-31, 2012. e-Pub 2012. PMID: 22397654.
124. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400-4, 2012. e-Pub 2012. PMID: 22318521.
125. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol 188(3):976-80, 2012. e-Pub 2012. PMID: 22198953.
126. Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G, Allison JP. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A 109(3):881-6, 2012. e-Pub 2012. PMID: 22223661.
127. Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 72(2):430-9, 2012. e-Pub 2012. PMID: 22108823.
128. Srivastava PK, Cerundolo V, Knuth A, Allison JP. An open invitation to the cancer immunology community. Cancer Immun 12:1, 2012. e-Pub 2012. PMID: 22896746.
129. Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One 7(4):e35222, 2012. e-Pub 2012. PMID: 22493742.
130. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108(40):16723-8, 2011. e-Pub 2011. PMID: 21933959.
131. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, DeMatteo RP. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17(9):1094-100, 2011. e-Pub 2011. PMID: 21873989.
132. Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med 208(8):1683-94, 2011. e-Pub 2011. PMID: 21727190.
133. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 35(1):123-34, 2011. e-Pub 2011. PMID: 21757379.
134. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6(4):e19499, 2011. e-Pub 2011. PMID: 21559358.
135. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A 108(1):266-71, 2011. e-Pub 2011. PMID: 21173239.
136. Corse E, Gottschalk RA, Krogsgaard M, Allison JP. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol 8(9), 2010. e-Pub 2010. PMID: 20856903.
137. Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med 207(8):1701-11, 2010. e-Pub 2010. PMID: 20660617.
138. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23(8):1104-12, 2010. e-Pub 2010. PMID: 20495537.
139. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16(10):2781-91, 2010. e-Pub 2010. PMID: 20460483.
140. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 2010. e-Pub 2010. PMID: 20460488.
141. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116(7):1767-75, 2010. e-Pub 2010. PMID: 20143434.
142. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207(3):637-50, 2010. e-Pub 2010. PMID: 20156971.
143. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107(9):4275-80, 2010. e-Pub 2010. PMID: 20160101.
144. Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 10:1, 2010. e-Pub 2010. PMID: 20052966.
145. Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 69(19):7747-55, 2009. e-Pub 2009. PMID: 19738077.
146. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206(8):1717-25, 2009. e-Pub 2009. PMID: 19581407.
147. Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy 1(1):129-39, 2009. e-Pub 2009. PMID: 20445772.
148. Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 11(7):912-22, 2009. e-Pub 2009. PMID: 19903103.
149. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105(51):20410-5, 2008. e-Pub 2008. PMID: 19074257.
150. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 205(9):2125-38, 2008. e-Pub 2008. PMID: 18725522.
151. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112(4):1175-83, 2008. e-Pub 2008. PMID: 18523152.
152. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 68(15):6054-8, 2008. e-Pub 2008. PMID: 18676826.
153. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 57(8):1263-70, 2008. e-Pub 2008. PMID: 18236040.
154. Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A 105(9):3509-14, 2008. e-Pub 2008. PMID: 18303116.
155. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105(8):3005-10, 2008. e-Pub 2008. PMID: 18287062.
156. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res 68(3):889-92, 2008. e-Pub 2008. PMID: 18245491.
157. Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 319(5860):215-20, 2008. e-Pub 2008. PMID: 18187659.
158. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 104(49):19458-63, 2007. e-Pub 2007. PMID: 18042703.
159. Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A 104(45):17765-70, 2007. e-Pub 2007. PMID: 17968013.
160. Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, Allen JE. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 179(6):3926-36, 2007. e-Pub 2007. PMID: 17785830.
161. Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood 110(3):954-61, 2007. e-Pub 2007. PMID: 17483299.
162. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158-67, 2007. e-Pub 2007. PMID: 17404100.
163. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13(6):1810-5, 2007. e-Pub 2007. PMID: 17363537.
164. Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H, Xiao H, Dilorenzo TP, Allison JP, Nathenson SG, Almo SC. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 26(3):311-21, 2007. e-Pub 2007. PMID: 17363302.
165. Zang X, Loke P, Kim J, Wojnoonski K, Kusdra L, Allison JP. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics 88(6):841-845, 2006. e-Pub 2006. PMID: 17014982.
166. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 177(2):1052-61, 2006. e-Pub 2006. PMID: 16818761.
167. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935-45, 2006. e-Pub 2006. PMID: 16778987.
168. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-7, 2006. e-Pub 2006. PMID: 16382236.
169. Williams JA, Hathcock KS, Klug D, Harada Y, Choudhury B, Allison JP, Abe R, Hodes RJ. Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. J Immunol 175(7):4199-207, 2005. e-Pub 2005. PMID: 16177059.
170. Loke P, Zang X, Hsuan L, Waitz R, Locksley RM, Allen JE, Allison JP. Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proc Natl Acad Sci U S A 102(28):9872-7, 2005. e-Pub 2005. PMID: 15994233.
171. Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol 174(4):1922-31, 2005. e-Pub 2005. PMID: 15699119.
172. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. 1982. J Immunol 174(3):1144-51, 2005. e-Pub 2005. PMID: 15661866.
173. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11(2 Pt 1):728-34, 2005. e-Pub 2005. PMID: 15701862.
174. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 173(10):6098-108, 2004. e-Pub 2004. PMID: 15528346.
175. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21(3):401-13, 2004. e-Pub 2004. PMID: 15357951.
176. Stohl W, Xu D, Kim KS, David CS, Allison JP. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol 16(7):895-904, 2004. e-Pub 2004. PMID: 15136557.
177. Mamura M, Lee W, Sullivan TJ, Felici A, Sowers AL, Allison JP, Letterio JJ. CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood 103(12):4594-601, 2004. e-Pub 2004. PMID: 15016653.
178. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22(13-14):1700-8, 2004. e-Pub 2004. PMID: 15068853.
179. Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol 172(1):34-9, 2004. e-Pub 2004. PMID: 14688306.
180. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 100(18):10388-92, 2003. e-Pub 2003. PMID: 12920180.
181. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100(14):8372-7, 2003. e-Pub 2003. PMID: 12826605.
182. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4(7):670-9, 2003. e-Pub 2003. PMID: 12796776.
183. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 100(9):5336-41, 2003. e-Pub 2003. PMID: 12697896.
184. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100(8):4712-7, 2003. e-Pub 2003. PMID: 12682289.
185. Prilliman KR, Lemmens EE, Palioungas G, Wolfe TG, Allison JP, Sharpe AH, Schoenberger SP. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J Immunol 169(8):4094-7, 2002. e-Pub 2002. PMID: 12370335.
186. Chambers CA, Kang J, Wu Y, Held W, Raulet DH, Allison JP. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood 99(12):4509-16, 2002. e-Pub 2002. PMID: 12036882.
187. Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A 99(5):3013-7, 2002. e-Pub 2002. PMID: 11867713.
188. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16(1):23-35, 2002. e-Pub 2002. PMID: 11825563.
189. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194(6):823-32, 2001. e-Pub 2001. PMID: 11560997.
190. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194(4):481-9, 2001. e-Pub 2001. PMID: 11514604.
191. Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP. Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc Natl Acad Sci U S A 98(5):2587-92, 2001. e-Pub 2001. PMID: 11226283.
192. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409(6816):97-101, 2001. e-Pub 2001. PMID: 11343121.
193. Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci U S A 97(23):12711-6, 2000. e-Pub 2000. PMID: 11050166.
194. Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A 97(22):12204-9, 2000. e-Pub 2000. PMID: 11035773.
195. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60(9):2444-8, 2000. e-Pub 2000. PMID: 10811122.
196. Yu X, Fournier S, Allison JP, Sharpe AH, Hodes RJ. The role of B7 costimulation in CD4/CD8 T cell homeostasis. J Immunol 164(7):3543-53, 2000. e-Pub 2000. PMID: 10725709.
197. Piganelli JD, Poulin M, Martin T, Allison JP, Haskins K. Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. J Autoimmun 14(2):123-31, 2000. e-Pub 2000. PMID: 10677243.
198. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 96(26):15074-9, 1999. e-Pub 1999. PMID: 10611340.
199. Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 96(20):11476-81, 1999. e-Pub 1999. PMID: 10500201.
200. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355-66, 1999. e-Pub 1999. PMID: 10430624.
201. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A 96(15):8603-8, 1999. e-Pub 1999. PMID: 10411922.
202. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162(10):5813-20, 1999. e-Pub 1999. PMID: 10229815.
203. Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol 28(10):3137-43, 1998. e-Pub 1998. PMID: 9808182.
204. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 95(17):10067-71, 1998. e-Pub 1998. PMID: 9707601.
205. Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. J Exp Med 188(4):651-9, 1998. e-Pub 1998. PMID: 9705947.
206. Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 77(1):107-13, 1998. e-Pub 1998. PMID: 9639401.
207. Lühder F, Höglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 187(3):427-32, 1998. e-Pub 1998. PMID: 9449722.
208. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7(6):885-95, 1997. e-Pub 1997. PMID: 9430233.
209. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 159(7):3460-73, 1997. e-Pub 1997. PMID: 9317145.
210. Zhang Y, Allison JP. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A 94(17):9273-8, 1997. e-Pub 1997. PMID: 9256472.
211. Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A 94(17):9296-301, 1997. e-Pub 1997. PMID: 9256476.
212. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 94(15):8099-103, 1997. e-Pub 1997. PMID: 9223321.
213. Liao XC, Fournier S, Killeen N, Weiss A, Allison JP, Littman DR. Itk negatively regulates induction of T cell proliferation by CD28 costimulation. J Exp Med 186(2):221-8, 1997. e-Pub 1997. PMID: 9221751.
214. Fournier S, Rathmell JC, Goodnow CC, Allison JP. T cell-mediated elimination of B7.2 transgenic B cells. Immunity 6(3):327-39, 1997. e-Pub 1997. PMID: 9075933.
215. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 73(1-2):57-62, 1997. e-Pub 1997. PMID: 9058759.
216. Chambers CA, Allison JP. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. Eur J Immunol 26(12):3224-9, 1996. e-Pub 1996. PMID: 8977326.
217. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183(6):2533-40, 1996. e-Pub 1996. PMID: 8676074.
218. Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8(4):519-23, 1996. e-Pub 1996. PMID: 8671638.
219. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-6, 1996. e-Pub 1996. PMID: 8596936.
220. Liu B, Podack ER, Allison JP, Malek TR. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 156(3):1117-25, 1996. e-Pub 1996. PMID: 8557987.
221. Zhang Y, Cado D, Asarnow DM, Komori T, Alt FW, Raulet DH, Allison JP. The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. Immunity 3(4):439-47, 1995. e-Pub 1995. PMID: 7584135.
222. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459-65, 1995. e-Pub 1995. PMID: 7543139.
223. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54(24):6477-83, 1994. e-Pub 1994. PMID: 7527298.
224. Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol 152(7):3361-9, 1994. e-Pub 1994. PMID: 7511644.
225. Holsti MA, McArthur J, Allison JP, Raulet DH. Role of IL-6, IL-1, and CD28 signaling in responses of mouse CD4+ T cells to immobilized anti-TCR monoclonal antibody. J Immunol 152(4):1618-28, 1994. e-Pub 1994. PMID: 7907103.
226. Nandi D, Allison JP. Characterization of neutrophils and T lymphocytes associated with the murine vaginal epithelium. Reg Immunol 5(6):332-8, 1993. e-Pub 1993. PMID: 8068536.
227. Clements JL, Winslow G, Donahue C, Cooper SM, Allison JP, Budd RC. Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. Int Immunol 5(11):1451-60, 1993. e-Pub 1993. PMID: 7903158.
228. Sagerström CG, Kerr EM, Allison JP, Davis MM. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A 90(19):8987-91, 1993. e-Pub 1993. PMID: 8415642.
229. Page DM, Kane LP, Allison JP, Hedrick SM. Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol 151(4):1868-80, 1993. e-Pub 1993. PMID: 7688388.
230. Giese T, Allison JP, Davidson WF. Functionally anergic lpr and gld B220+ T cell receptor (TCR)-alpha/beta+ double-negative T cells express CD28 and respond to costimulation with phorbol myristate acetate and antibodies to CD28 and the TCR. J Immunol 151(2):597-609, 1993. e-Pub 1993. PMID: 7687618.
231. Leclercq G, Plum J, Nandi D, De Smedt M, Allison JP. Intrathymic differentiation of V gamma 3 T cells. J Exp Med 178(1):309-15, 1993. e-Pub 1993. PMID: 8315386.
232. Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177(6):1791-6, 1993. e-Pub 1993. PMID: 7684435.
233. Wells FB, Tatsumi Y, Bluestone JA, Hedrick SM, Allison JP, Matis LA. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. J Exp Med 177(4):1061-70, 1993. e-Pub 1993. PMID: 8459203.
234. Gramzinski RA, Adams E, Gross JA, Goodman TG, Allison JP, Lefrançois L. T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. Int Immunol 5(2):145-53, 1993. e-Pub 1993. PMID: 8383994.
235. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259(5093):368-70, 1993. e-Pub 1993. PMID: 7678351.
236. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 149(2):380-8, 1992. e-Pub 1992. PMID: 1320641.
237. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356(6370):607-9, 1992. e-Pub 1992. PMID: 1313950.
238. Nandi D, Allison JP. Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol 147(6):1773-8, 1991. e-Pub 1991. PMID: 1679835.
239. Havran WL, Chien YH, Allison JP. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science 252(5011):1430-2, 1991. e-Pub 1991. PMID: 1828619.
240. Glaichenhaus N, Davis C, Bornschlegel K, Allison JP, Shastri N. A novel strategy for the generation of T cell lines lacking expression of endogenous alpha- and/or beta-chain T cell receptor genes. J Immunol 146(7):2095-101, 1991. e-Pub 1991. PMID: 1826016.
241. Iwashima M, Green A, Bonyhadi M, Davis MM, Allison JP, Chien YH. Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. Int Immunol 3(4):385-93, 1991. e-Pub 1991. PMID: 1831656.
242. Lotscher E, Allison JP. Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. Nucleic Acids Res 18(23):7153, 1990. e-Pub 1990. PMID: 2263486.
243. Mitchell DL, Allison JP, Nairn RS. Immunoprecipitation of pyrimidine(6-4)pyrimidone photoproducts and cyclobutane pyrimidine dimers in uv-irradiated DNA. Radiat Res 123(3):299-303, 1990. e-Pub 1990. PMID: 2217727.
244. Ferrick DA, Chan A, Rahemtulla A, Widacki SM, Xia M, Broughton H, Gajewski DA, Ballhausen W, Allison JP, Bluestone JA. Expression of a T cell receptor gamma-chain (V gamma 1.1J gamma 4C gamma 4) transgene in mice influences T cell receptor ontogeny and thymic architecture during development. J Immunol 145(1):20-7, 1990. e-Pub 1990. PMID: 2141615.
245. Riegel JS, Richie ER, Allison JP. Nuclear events after activation of CD4+8+ thymocytes. J Immunol 144(9):3611-8, 1990. e-Pub 1990. PMID: 1970353.
246. Gross JA, St John T, Allison JP. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol 144(8):3201-10, 1990. e-Pub 1990. PMID: 2157764.
247. Havran WL, Allison JP. Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature 344(6261):68-70, 1990. e-Pub 1990. PMID: 1968230.
248. Asarnow DM, Goodman T, LeFrancois L, Allison JP. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature 341(6237):60-2, 1989. e-Pub 1989. PMID: 2528075.
249. Strober S, Dejbachsh-Jones S, Van Vlasselaer P, Duwe G, Salimi S, Allison JP. Cloned natural suppressor cell lines express the CD3+CD4-CD8- surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor. J Immunol 143(4):1118-22, 1989. e-Pub 1989. PMID: 2526181.
250. Havran WL, Grell S, Duwe G, Kimura J, Wilson A, Kruisbeek AM, O'Brien RL, Born W, Tigelaar RE, Allison JP. Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proc Natl Acad Sci U S A 86(11):4185-9, 1989. e-Pub 1989. PMID: 2726770.
251. Duplay P, Lancki D, Allison JP. Distribution and ontogeny of CD2 expression by murine T cells. J Immunol 142(9):2998-3005, 1989. e-Pub 1989. PMID: 2565352.
252. Kyewski BA, Schirrmacher V, Allison JP. Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. Eur J Immunol 19(5):857-63, 1989. e-Pub 1989. PMID: 2525475.
253. Havran WL, Poenie M, Tigelaar RE, Tsien RY, Allison JP. Phenotypic and functional analysis of gamma delta T cell receptor-positive murine dendritic epidermal clones. J Immunol 142(5):1422-8, 1989. e-Pub 1989. PMID: 2783942.
254. Marusic-Galesic S, Saito T, Tentori L, Zuñiga-Pflucker J, Raulet DH, Allison JP, Kruisbeek AM. A novel gamma delta T cell receptor for antigen adds limited diversity to the gamma delta repertoire in adult thymus. J Immunol 142(1):28-34, 1989. e-Pub 1989. PMID: 2521236.
255. Groghan TW, Davignon JL, Evans J, Allison JP, Eisenberg RA, Frelinger JA, Cohen PL. Diminished expression of the T cell receptor on the expanded lymphocyte population in MRL/Mp-lpr/lpr mice. Autoimmunity 2(2):97-111, 1989. e-Pub 1989. PMID: 2562377.
256. Nairn RS, McIntyre BW, Richie ER, Allison JP. Characterization of env gene recombination in x-ray--induced thymomas of C57BL/6 mice. Mol Carcinog 2(3):126-30, 1989. e-Pub 1989. PMID: 2675902.
257. Asarnow DM, Kuziel WA, Bonyhadi M, Tigelaar RE, Tucker PW, Allison JP. Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell 55(5):837-47, 1988. e-Pub 1988. PMID: 2847872.
258. Havran WL, Allison JP. Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature 335(6189):443-5, 1988. e-Pub 1988. PMID: 2458531.
259. Richie ER, McEntire B, Phillips J, Allison JP. Altered expression of lymphocyte differentiation antigens on phorbol ester-activated CD4+8+ T cells. J Immunol 140(12):4115-22, 1988. e-Pub 1988. PMID: 3259607.
260. Richie ER, McEntire B, Crispe N, Kimura J, Lanier LL, Allison JP. Alpha/beta T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation. Proc Natl Acad Sci U S A 85(4):1174-8, 1988. e-Pub 1988. PMID: 2963339.
261. Allison JP, Havran WL, Asarnow D, Tigelaar RE, Tucker PW, Bonyhadi M. Gamma delta antigen receptors of Thy-1+ dendritic epidermal cells: implications for thymic differentiation. Immunol Res 7(4):292-302, 1988. e-Pub 1988. PMID: 2906352.
262. Bonyhadi M, Weiss A, Tucker PW, Tigelaar RE, Allison JP. Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature 330(6148):574-6, 1987. e-Pub 1987. PMID: 3500417.
263. Crispe IN, Shimonkevitz RP, Husmann LA, Kimura J, Allison JP. Expression of T cell antigen receptor beta-chains on subsets of mouse thymocytes. Analysis by three-color flow cytometry. J Immunol 139(11):3585-9, 1987. e-Pub 1987. PMID: 2960738.
264. Havran WL, Poenie M, Kimura J, Tsien R, Weiss A, Allison JP. Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature 330(6144):170-3, 1987. e-Pub 1987. PMID: 2959867.
265. Kuziel WA, Takashima A, Bonyhadi M, Bergstresser PR, Allison JP, Tigelaar RE, Tucker PW. Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature 328(6127):263-6, 1987. e-Pub 1987. PMID: 2885757.
266. O'Neill HC, McGrath MS, Allison JP, Weissman IL. A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell 49(1):143-51, 1987. e-Pub 1987. PMID: 2435413.
267. Lanier LL, Federspiel NA, Ruitenberg JJ, Phillips JH, Allison JP, Littman D, Weiss A. The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med 165(4):1076-94, 1987. e-Pub 1987. PMID: 2435832.
268. Nagasawa R, Gross J, Kanagawa O, Townsend K, Lanier LL, Chiller J, Allison JP. Identification of a novel T cell surface disulfide-bonded dimer distinct from the alpha/beta antigen receptor. J Immunol 138(3):815-24, 1987. e-Pub 1987. PMID: 2433330.
269. Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol 137(8):2501-7, 1986. e-Pub 1986. PMID: 3531334.
270. Lanier LL, Ruitenberg JJ, Allison JP, Weiss A. Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. J Immunol 137(7):2286-92, 1986. e-Pub 1986. PMID: 2428866.
271. Saunders PH, McIntyre BW, Lawlor DA, Bridges WJ, Allison JP. The congenic mutant B6.C-H-2bm-1 (H-2bm-1) serological response to the T-cell receptor on EL4. Cell Immunol 101(2):586-92, 1986. e-Pub 1986. PMID: 3757049.
272. Allison JP, McIntyre BW, Ridge LL, Gross-Pelose J, Lanier LL. Molecular characterization of the murine T cell antigen receptor and associated structures. Fed Proc 44(13):2870-3, 1985. e-Pub 1985. PMID: 2412897.
273. Hixson DC, Allison JP. Monoclonal antibodies recognizing oval cells induced in the liver of rats by N-2-fluorenylacetamide or ethionine in a choline-deficient diet. Cancer Res 45(8):3750-60, 1985. e-Pub 1985. PMID: 2410100.
274. Walborg EF, Tsuchida S, Weeden DS, Thomas MW, Barrick A, McEntire KD, Allison JP, Hixson DC. Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Exp Cell Res 158(2):509-18, 1985. e-Pub 1985. PMID: 3891389.
275. Allison JP, Lanier LL. Identification of antigen receptor-associated structures on murine T cells. Nature 314(6006):107-9, 1985. e-Pub 1985. PMID: 2579338.
276. Allison JP, McIntyre BW, Richie ER. Correlation of antigen receptor expression and surface phenotype of murine lymphomas. Fed Proc 44:2222, 1985. e-Pub 1985.
277. McIntyre BW, Allison JP. Biosynthesis and processing of murine T-cell antigen receptor. Cell 38(3):659-65, 1984. e-Pub 1984. PMID: 6488315.
278. Kline K, Allison JP, McIntyre BW, Sanders BG. Immunochemical characterization of differentiation and age-related cell surface antigens expressed by chicken erythrocytes. Cancer Res 44(8):3576-83, 1984. e-Pub 1984. PMID: 6378372.
279. Hixson DC, DeLourdes Ponce M, Allison JP, Walborg EF. Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. Exp Cell Res 152(2):402-14, 1984. e-Pub 1984. PMID: 6723795.
280. Hixson DC, Allison JP, McEntire KD, Nairn RS, Chesner JE, Walborg EF. Structural differences in envelope glycoproteins associated with rat leukaemia virus produced by Novikoff hepatocellular carcinoma and spontaneously transformed Wistar rat embryo cells. J Gen Virol 65 (Pt 4):743-60, 1984. e-Pub 1984. PMID: 6368746.
281. Pellegrino MA, Russo C, Allison JP. HLA antigens in serum. Methods Enzymol 108:614-24, 1984. e-Pub 1984. PMID: 6527659.
282. Kappler J, Kubo R, Haskins K, Hannum C, Marrack P, Pigeon M, McIntyre B, Allison J, Trowbridge I. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell 35(1):295-302, 1983. e-Pub 1983. PMID: 6605199.
283. McIntyre BW, Allison JP. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 34(3):739-46, 1983. e-Pub 1983. PMID: 6194888.
284. Hixson DC, Allison JP, Chesner JE, Leger MJ, Ridge LL, Walborg EF. Characterization of a family of glycoproteins associated with the bile canalicular membrane of normal hepatocytes but not expressed by two transplantable rat hepatocellular carcinomas. Cancer Res 43(8):3874-84, 1983. e-Pub 1983. PMID: 6344992.
285. Callahan GN, Pardi D, Giedlin MA, Allison JP, Morizot DM, Martin WJ. Biochemical evidence for expression of a semi-allogeneic, H-2 antigen by a murine adenocarcinoma. J Immunol 130(1):471-9, 1983. e-Pub 1983. PMID: 6847892.
286. Lanier LL, Richie ER, Howell AL, Allison JP. Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma. Immunogenetics 17(6):655-9, 1983. e-Pub 1983. PMID: 6602763.
287. Howell AL, Richie ER, Dennison DK, Chan JYH, Allison JP. Individual AKR lymphomas differ in expression of lymphocyte differentiation antigens and terminal deoxynucleotidyl transferase. Disease Markers 1:3-18, 1983. e-Pub 1983.
288. Sanders BG, Allison JP, Kline K. Monoclonal antibody to chicken fetal antigens on normal erythroid cells and hematopoietic-lymphoid tumor cell lines. Cancer Res 42(11):4532-9, 1982. e-Pub 1982. PMID: 6751524.
289. Nelson CH, Allison JP, Kline K, Sanders BG. Chicken fetal and adult antigen expression on erythroleukemia cells before and after induced differentiation. Cancer Res 42(11):4625-30, 1982. e-Pub 1982. PMID: 7127300.
290. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol 129(5):2293-300, 1982. e-Pub 1982. PMID: 6181166.
291. Kline K, Allison JP, Sanders BG. Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. Dev Biol 91(2):389-96, 1982. e-Pub 1982. PMID: 6178635.
292. LeGrue SJ, Allison JP, Macek CM, Pellis NR, Kahan BD. Immunobiological properties of 1-butanol-extracted cell surface antigens. Cancer Res 41(10):3956-60, 1981. e-Pub 1981. PMID: 7026027.
293. Glenney JR, Allison JP, Hixson DC, Walborg EF. Resolution and partial characterization of the major plasma membrane sialoglycoproteins of Novikoff tumor cells. J Biol Chem 254(18):9247-53, 1979. e-Pub 1979. PMID: 479193.
294. Callahan GN, Allison JP, Pellegrino MA, Reisfeld RA. Physical association of histocompatibility antigens and tumor-associated antigens on the surface of murine lymphoma cells. J Immunol 122(1):70-4, 1979. e-Pub 1979. PMID: 762424.
295. Allison JP, Ferrone S, Walker LE, Pellegrino MA, Silver J, Reisfeld RA. Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. Transplantation 26(6):451-4, 1978. e-Pub 1978. PMID: 569916.
296. Allison JP, Belvedere M, Reisfeld RA, Pellegrino MA, Ferrone S. Serologic and immunochemical characterization of HLA-A9 xenoantisera. J Immunol 121(2):579-85, 1978. e-Pub 1978. PMID: 681750.
297. Allison JP, Walker LE, Russell WA, Pellegrino MA, Ferrone S, Reisfeld RA, Frelinger JA, Silver J. Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A 75(8):3953-6, 1978. e-Pub 1978. PMID: 99745.
298. Callahan GN, Allison JP. H-2 antigens on a murine lymphoma are associated with additional proteins. Nature 271(5641):165-7, 1978. e-Pub 1978. PMID: 74802.
299. Callahan GN, Pellegrino MA, McCabe RP, Frugis L, Allison JP, Ferrone S. Histocompatibility antigens on tumor cells: spatial and structural relationships with tumor-associated antigens. Behring Inst Mitt 62:115-28, 1978. e-Pub 1978.
300. Allison JP, Pellegrino MA, Reisfeld RA, Ferrone S. An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. Transplant Proc 9(4):1691-3, 1977. e-Pub 1977. PMID: 74875.
301. Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. J Immunol 118(3):1004-9, 1977. e-Pub 1977. PMID: 191523.
302. Allison JP, Ferrone S, Pellegrino MA, Reisfeld RA. Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. Transplant Proc 9(1):601-4, 1977. e-Pub 1977. PMID: 194373.
303. Ferrone S, Mittal KK, Pellegrino MA, Allison JP, Reisfeld RA. Immunogenicity of HLA antigens purified from serum. Transplantation 23(1):7-15, 1977. e-Pub 1977. PMID: 65035.
304. Ferrone S, Pellegrino MA, Allison JP, Reisfeld RA. Biological and chemical aspects of histocompatibility antigens in serum. Haematologica 61(4):397-417, 1976. e-Pub 1976. PMID: 828605.
305. Reisfeld RA, Allison JP, Ferrone S, Pellegrino MA, Poulik MD. HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. Transplant Proc 8(2):173-8, 1976. e-Pub 1976. PMID: 59439.
306. Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Detection of H-2 antigens in serum. Transplantation 20(5):431-3, 1975. e-Pub 1975. PMID: 174256.
307. Prager MD, Ludden CM, Mandy WJ, Allison JP, Kitto GB. Endotoxin-stimulated immune response to modified lymphoma cells. J Natl Cancer Inst 54(3):773-5, 1975. e-Pub 1975. PMID: 1168264.
308. Allison JP, Davidson L, Gutierrez-Hartman A, Kitto GB. Insolubilization of L-asparaginase by covalent attachment to nylon tubing. Biochem Biophys Res Commun 47(1):66-73, 1972. e-Pub 1972. PMID: 5027141.
309. Allison JP, Mandy WJ, Kitto GB. The substrate specificity of L-asparaginase from Alcaligenes eutrophus. FEBS Lett 14(2):107-8, 1971. e-Pub 1971. PMID: 11945731.

Invited Articles

1. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069-1086, 2018. e-Pub 2018. PMID: 30115704.
2. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205-14, 2015. e-Pub 2015. PMID: 25860605.
3. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3(7):611-8, 2002. e-Pub 2002. PMID: 12087419.
4. Lanier LL, Serafini AT, Ruitenberg JJ, Cwirla S, Federspiel NA, Phillips JH, Allison JP, Weiss A. The gamma T-cell antigen receptor. J Clin Immunol 7(6):429-40, 1987. e-Pub 1987. PMID: 3320076.

Review Articles

1. Chaib M, Allison JP. Local T(reg) cell loss reprogrammes systemic antitumour immunity without breaking tolerance. Nat Rev Immunol 26(1):5, 2026. e-Pub 2026. PMID: 41298974.
2. Di Giacomo AM, Lahn M, Eggermont AM, Fox B, Ibrahim R, Sharma P, Allison JP, Maio M. The future of targeting cytotoxic T-lymphocyte-associated protein-4. Eur J Cancer 198:113501, 2024. e-Pub 2024. PMID: 38169219.
3. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy—current perspectives and future directions. Cell 186(8):1652-1669, 2023. e-Pub 2023. PMID: 37059068.
4. Sharma P, Allison JP. Immune checkpoint therapy. Sci Transl Med 14(670):eadf2947, 2022. e-Pub 2022. PMID: 36350993.
5. Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. e-Pub 2021. PMID: 33811120.
6. Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32(5):1094-105, 2018. e-Pub 2018. PMID: 29487386.
7. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR, Elmunzer BJ, Laiyemo AO, Mendez J, Somsouk M, Allison J, Bhuket T, Geng Z, Green BB, Itzkowitz SH, Martinez ME. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst 106(4):dju032, 2014. e-Pub 2014. PMID: 24681602.
8. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 60(8):1137-46, 2011. e-Pub 2011. PMID: 21465316.
9. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol 186(9):5039-45, 2011. e-Pub 2011. PMID: 21505216.
10. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37(5):473-84, 2010. e-Pub 2010. PMID: 21074063.
11. Chambers CA, Allison JP. CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol 64:303-12, 1999. e-Pub 1999. PMID: 11232300.
12. Allison JP, Havran WL. The immunobiology of T cells with invariant gamma delta antigen receptors. Annu Rev Immunol 9:679-705, 1991. e-Pub 1991. PMID: 1832874.

Other Articles

1. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA Author Correction. Nature 615(7953):E23, 2023. PMID: 36894629.
2. Ferrarotto, R, Amit, M, Nagarajan, P, Rubin, ML, Yuan, Y, Bell, D, El-Naggar, AK, Johnson, JM, Morrison, WH, Rosenthal, D, Glisson, BS, Johnson, FM, Lu, C, Mott, FE, Esmaeli, B, Diaz Jr, EM, Gidley, PW, Goepfert, RP, Lewis, CM, Weber, RS, Wargo, J, Basu, S, Duan, F, Yadav, SS, Sharma, P, Allison, JP, Myers, JN, Gross, N Erratum. Clinical Cancer Research 28(8):1735, 2022. PMID: 35419587.

Editorials

1. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 15(12):2574, 2025. PMID: 41327972.
2. Chaib M, Allison JP. Tumour cells mimic erythroblasts to hijack iron from bone marrow macrophages. Nat Rev Immunol 25(8):557, 2025. PMID: 40596685.
3. Agac Cobanoglu D, Allison JP. Neutrophils are dispensable for Shigella control: macrophages take centre stage. Nat Rev Immunol 25(4):233, 2025. PMID: 40044812.
4. Sharma, P, Allison, JP. Cancer Immunology and Immunotherapy Showcased in the AACR Cancer Progress Report 2023. Cancer Immunology Research 11(10):1298-1299, 2023. PMID: 37702540.
5. Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res 25(11):3469-3470, 2019. PMID: 31160495.
6. Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-risking immunotherapy: report of a consensus workshop of the cancer immunotherapy consortium of the Cancer Research Institute. Cancer Immunol Res 4(4):279-88, 2016. PMID: 27036972.
7. Allison J, Neill US. A conversation with James Allison. J Clin Invest 126(1):3-4, 2016. PMID: 26727227.
8. Allison JP. Immune checkpoint blockade in cancer therapy: the 2015 Lasker-DeBakey Clinical Medical Research Award. JAMA 314(11):1113-4, 2015. PMID: 26348357.
9. Allison JP. Checkpoints. Cell 162(6):1202-5, 2015. PMID: 26359978.
10. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230):56-61, 2015. PMID: 25838373.
11. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. PMID: 26310908.
12. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol Res 2(9):831-8, 2014. PMID: 25187273.
13. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 65:185-202, 2014. PMID: 24188664.
14. Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol 20(9):3106-11, 2013. PMID: 23681603.
15. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 1291:1-13, 2013. PMID: 23772560.
16. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10:205, 2012. PMID: 23034130.
17. Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 1(4):544-6, 2012. PMID: 22754781.
18. Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology 217(6):590-2, 2012. PMID: 22459268.
19. Sharma P, Allison JP. Retrospective. Lloyd J. Old (1933-2011). Science 335(6064):49, 2012. PMID: 22223799.
20. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 12:14, 2012. PMID: 22896759.
21. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214, 2011. PMID: 22168571.
22. Allison JP, Benoist C, Chervonsky AV. Nobels: Toll pioneers deserve recognition. Nature 479(7372):178, 2011. PMID: 22071753.
23. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11(11):805-12, 2011. PMID: 22020206.
24. Krummel MF, Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. J Immunol 187(7):3459-65, 2011. PMID: 21934097.
25. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 241(1):104-18, 2011. PMID: 21488893.
26. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 22(3):326-32, 2010. PMID: 20116985.
27. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323-37, 2009. PMID: 19723653.
28. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 157(1):9-19, 2009. PMID: 19659765.
29. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 229(1):67-87, 2009. PMID: 19426215.
30. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 224:141-65, 2008. PMID: 18759925.
31. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13(18 Pt 1):5271-9, 2007. PMID: 17875755.
32. Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12(3):192-9, 2007. PMID: 17785201.
33. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol 34(2):165-72, 2007. PMID: 17382800.
34. Zang X, Allison JP. To be or not to be B7. J Clin Invest 116(10):2590-3, 2006. PMID: 17016555.
35. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 24(5):442-7, 2006. PMID: 16962497.
36. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18(2):206-13, 2006. PMID: 16464564.
37. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339, 2006. PMID: 16730267.
38. Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol 6(12):1207-10, 2005. PMID: 16369561.
39. Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 130(6):809-24, 2005. PMID: 16156851.
40. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10(9):887-92, 2004. PMID: 15340404.
41. Loke P, Allison JP. Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res Ther 6(5):208-14, 2004. PMID: 15380035.
42. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer: advances in immunotherapy. BioDrugs 17(2):131-8, 2003. PMID: 12641491.
43. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol Chapter 20:Unit 20.5, 2001. PMID: 18432778.
44. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-94, 2001. PMID: 11244047.
45. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 11(2):203-10, 1999. PMID: 10209159.
46. Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?. Novartis Found Symp 215:92-8; discussion 98-102, 186-90, 1998. PMID: 9760573.
47. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 7(4):445-50, 1997. PMID: 9354465.
48. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 9(3):396-404, 1997. PMID: 9203422.
49. Nussenzweig M, Allison JP. Lymphocyte activation and effector functions. How signals are integrated in the immune system. Curr Opin Immunol 9(3):293-5, 1997. PMID: 9203423.
50. Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27-46, 1996. PMID: 9010718.
51. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 270(5238):932-3, 1995. PMID: 7481795.
52. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 7(5):682-6, 1995. PMID: 8573312.
53. Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 16(7):306-10, 1995. PMID: 7576059.
54. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 6(3):414-9, 1994. PMID: 7522466.
55. Allison JP. Gamma delta T-cell development. Curr Opin Immunol 5(2):241-6, 1993. PMID: 8389558.
56. Havran WL, Carbone A, Allison JP. Murine T cells with invariant gamma delta antigen receptors: origin, repertoire, and specificity. Semin Immunol 3(2):89-97, 1991. PMID: 1716172.
57. Allison JP, Raulet DH. The immunobiology of gamma delta+ T cells. Semin Immunol 2(1):59-65, 1990. PMID: 2151798.
58. Allison JP, Lanier LL. The T-cell antigen receptor gamma gene: rearrangement and cell lineages. Immunol Today 8(10):293-6, 1987. PMID: 25290833.
59. Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol 5:503-40, 1987. PMID: 2439105.
60. Allison JP, Ridge L, Lund J, Gross-Pelose J, Lanier L, McIntyre BW. The murine T cell antigen receptor and associated structures. Immunol Rev 81:145-60, 1984. PMID: 6210241.
61. Allison JP. Contributions of hybridoma technology to cancer immunology. The Cancer Bulletin 33:226-32, 1981.
62. Ferrone S, Allison JP, Pellegrino MA. Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol 7:239-81, 1978. PMID: 103685.

Abstracts

1. De Groot JF, Penas-Prado M, Mandel JJ, O'Brien BJ, Weathers SS, Zhou S, Hunter K, Alfaro-Munoz K, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, Ferguson SD, Yuan Y, Vence LM, Allison JP, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
2. Shi LZ, Gao J, Vence L, Brando J, Allison J, Sharma P. Adoptive transfer of tumor antigen-specifıc CTLs requires antiCTLA-4 and anti-PD-1 to drive tumor eradication. American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
3. Reuben A, Gittelman R, Zhang K, Quek K, Vence LM, Behrens C, Chen R, Fujimoto K, C-W C, Wu X, Allison JP, Sharma P, Zhang J, Lee JJ, Sepesi B, Gibbons DL, Heymach J, Futreal A, Wistuba II, Zhang J, Team I. The T cell receptor landscape is associated with survival in non-small cell lung cancer. 2018 American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium, San Francisco, CA, 2018. e-Pub 2018.
4. H-X G, Bhattacharya S, Matheny CJ, Yanamandra N, S-Y Z, Emerich H, Li Y, Bojczuk P, Shi H, Wang W, Hopson C, Fu T, Allison JP, Sharma P, Smothers JF, Srinivasan R, Hoos A. Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy. American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
5. Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VL II, Sharma P, Allison JP, Blando JM, Maru DM, Overman MJ, Kopetz S. Phosphatidylinositol 3-kinase (PI3K) pathway activation is associated with increased immune checkpoint expression in colorectal cancer (CRC) patients. 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 2018. e-Pub 2018.
6. Mok S, Duffy CR, Allison JP. Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse. American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
7. Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Lopez JH, Kornblau S, Andreeff M, Bueso-Ramos CE, Blando JM, Alatrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
8. Gao J, Karam JA, Tannir NM, Slack R, Ahrar K, Rao P, Ng CS, Jonasch E, Campbell MT, Matin SF, Zurita AJ, Wang J, Blando JM, Zhao H, Vence LM, Basu S, Chen H, Allison JP, Wood CG, Sharma P. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx). American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
9. Keung EZ, Glitza IC, Burton E, Amaria RN, Patel SP, Diab A, Yee C, Wong MK, W-J H, Hwu P, Woodman SE, Tetzlaff MT, Trujillo-Conley N, Milton DR, Davies MA, Rai K, Fernandez I, Blando JM, Vence LM, Sharma P, Allison JP, Wargo JA, Tawbi H. The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on immune infiltrates in metastatic melanoma (MM). American Association for Cancer Research Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
10. Sharma P, Dirix L, FYFL DV, Allison JP, Decoster L, Zaucha R, Park JH, Vanderwalde AM, Kataria RS, Ferro S, Patel G, Ben YB, D-Y O. Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 2018. e-Pub 2018.
11. Gao J, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campell M, Ng CS, Slack RS, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC 77(13 Supplement), 2017. e-Pub 2017.
12. Mok S, Duffy CR, Allison JP. Effects of anti-ctla-4 and anti-pd-1 on memory T-cell differentiation and resistance to tumor relapse. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC 77(13 Supplement), 2017. e-Pub 2017.
13. Gopalakrishnan V, Spencer C, Reuben A, Prieto P, Vicente D, Karpinets TV, Hudgens CW, Hutchinson DS, Tetzlaff M, Lazar A, Davies MA, Gershenwald JE, Jenq R, Hwu P, Sharma P, Allison J, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC 77(13 Supplement), 2017. e-Pub 2017.
14. Daver NG, Garcia-Manero G, Cortes JE, Basu S, Ravandi F, Kadia TM, Borthakur G, Jabbour E, Dinardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreef M, Konopleva M, Ning J, Allison JP, Sharma P, Kantarjian HM. Phase IB/II study of Iirilumab with azacytidine (AZA) in relapsed AML. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
15. Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreef M, Ning J, Kornblau S, Kadia TM, Dinardo CD, Konopleva M, Allison JP, Kantarjian HM, Sharma P. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
16. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, W-J H, Glitza IC, HA-H T, Patel SP, Lee JE, Davies MA, Gershenwald JE, Futreal A, Sharma P, Allison JP, Jenq RR. Association of the diversity and composition of the gut microbiome with responses and survival in metastatic melanoma patients on anti-PD-1 therapy. Proceedings of the American Association of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
17. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudha SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, Blando JM, Sepulveda MA, Sun JJ, Sharma P. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
18. Reilley M, Basu S, Katkhuda R, Patterson N, Chen T, Blando JM, Menter D, Maru DM, Allison JP, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
19. W-S C, Andrews MC, Spencer C, HA-H T, Lazar A, Tetzlaff MT, Patel SP, Hwu P, W-J H, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
20. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, C-J W, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstin M, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
21. Mok S, Duffy C, Du R, Allison JP. Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase (Trk) improves antitumor efficacy of immunotherapy. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston, MA 5(3 Supplement), 2017. e-Pub 2017.
22. Gopalakrishnan V, Spencer C, Reuben A, Karpinets T, Hutchinson D, Hoffman K, Prieto PA, Tetzlaff MT, Lazar A, Davies MA, Gershenwald JE, Jenq RR, Hwu P, Sharma P, Allison JP, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, 2017. e-Pub 2017.
23. Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, Fernandez-Cubelo I, Behrens C, Gao J, Yusko E, Emerson R, Benzeno S, Vignali M, Tipton C, Jalali A, W-C L, Li J, Wu X, Ye Y, Eterovic A, Little L, Gumbs C, Goplakarishnan V, Bernatchez C, Haymaker C, M-A F, Federico L, Cascone T, Robins H, Roarty E, Rodriguez J, Parra E, Wargo J, Allison J, Sharma P, Zhang J, Lee J, Sepesi B, Swisher S, Gibbons D, Heymach J, Futreal A, Wistuba I, Zhang J. Immune, molecular and T cell repertoire landscape of 235 resected non-small cell lung cancers, paired normal lung and peripheral blood mononuclear cells. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD, 2017. e-Pub 2017.
24. Reddy SM, Amaria RN, Spencer CN, Tetzlaff M, Reuben A, Andrews M, Wang L, Woodman S, Zhu H, Blando J, Vence L, Zhang S, Jiang H, Gopalakrishnan V, Hudgens C, Wani K, Tawbi H, Diab A, Glitza I, Patel S, W-J H, Wong M, Hwu P, Cormier J, Lucci A, Royal R, Lee JE, Simpson L, Burton EM, Gershenwald JE, Ross M, Allison J, Sharma P, Davies M, Wargo J. Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD, 2017. e-Pub 2017.
25. Sharma P, Sohn JH, Shin SJ, D-Y O, Keam B, Lee HJ, J-L C, Kalinka-Warzocha E, Langenberg M, Allison J, Ben Y, Kataria R, Ferro S, Asubonteng K, Dirix L. Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD, 2017. e-Pub 2017.
26. Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu BC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Allison J, Sharma P, Pierce S, Brandt M, Pike A, Cortes JE, Kantarjian HM. Phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA 130(815), 2017. e-Pub 2017.
27. Jaiswal A, Pudakalakatti S, Dutta P, Arthur L, Bartkowiak T, Ager C, Ivan C, Davies MA, Allison JP, Davis RE, Wargo J, Bhattacharya PK, Hong D, Curran MA. Metabolic adaptations establish immunotherapy resistance in melanoma. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD, 2017. e-Pub 2017.
28. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour DJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Flores W, Matthews J, DiNardo CD, Borthakur G, Konopleva M, Allison J, Sharma P, Kantarjian HM. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) and frontline elderly AML. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA 130(1345), 2017. e-Pub 2017.
29. Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Al-Hamal Z, Konopleva M, Ning J, L-C X, Hidalgo Lopez J, Kornblau S, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Alatrash G, Allison JP, Kantarjian HM, Sharma P, Daver N. Checkpoint expression by acute myeloid leukemia (AML) and the immune microenvironment suppresses adaptive immunity. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA 130(185), 2017. e-Pub 2017.
30. Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T, Vicente D, Prieto P, Hoffman K, Wei S, Cogdill A, Sanchez ER, McAllister F, Wong M, Davies M, Lazar A, Gershenwald J, Ajami N, Cooper Z, Petrosino J, Daniel-MacDougall C, Tetzlaff M, Allison J, Sharma P, Jenq R, Wargo J. Diversity and composition of the gut microbiome influences responses to anti-PD1-therapy through beneficial changes in innate and adaptive immunity. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD, 2017. e-Pub 2017.
31. Wei S, Levine J, Cogdill A, Zhao Y, N-A A, Andrews M, Sharma P, Wang J, Wargo J, Pe'er D, Allison J. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD, 2017. e-Pub 2017.
32. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Flores W, Matthews J, DiNardo CD, Borthakur G, Konopleva M, Allison J, Sharma P, Kantarjian HM. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) and frontline elderly AML. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, 2017. e-Pub 2017.
33. Wei SC, Levin JH, Pe’er D, Allison JP. Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC 77(13 Supplement), 2017. e-Pub 2017.
34. Allison, JP. Immune checkpoint blockade in cancer therapy: cellular mechanisms of anti-CTLA-4 and anti-PD1. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
35. Sharma N, Allison JP. Fc gamma receptor IV mediated depletion of tumor infiltrating regulatory T cells by anti-CTLA4 antibody is promoted by TLR1/2 agonist and hence its efficacy in anti-tumor combination therapy. Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY 4(11 Supplement), 2016. e-Pub 2016.
36. Mok S, Duffy C, Du R, Allison JP. Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase. Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY 4(11 Supplement), 2016. e-Pub 2016.
37. Massarelli E, Parra ER, Rogriguez-Canales J, Behrens C, Diao L, Blando J, Wang J, Byers LA, Wistuba II, Sharma P, Allison JP, Heymach JV. High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better survival in non-small cell lung cancer. Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY 4(11 Supplement), 2016. e-Pub 2016.
38. Reuben A, Spencer CN, Prieto PA, Miller JP, Mao X, W-S C, Cheung H, Jiang H, Haymaker C, De Macedo MP, Garber HR, P-L C, Gopalakrishnan V, Austin-Breneman J, Hudgens CW, Roszik J, Hwu P, Woodman SE, Chin L, Davies MA, Amaria RN, Patel SP, Lazar AJ, Tetzlaff MT, Dwyer KC, Wistuba II, Sharma P, Allison JP, Zhang J, Futreal A, Cooper ZA, Wargo JA. Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA 76(14 Supplement), 2016. e-Pub 2016.
39. Cortez MA, Wang X, Ivan C, Schoenhals JE, Niknam S, Li A, Valdecanas D, Allison JP, Sharma P, Overwijk WW, Gomez D, Chang JY, Hahn S, Calin GA, Welsh JW. MicroRNA-mediated resistance to anti-PD1 therapy in lung cancer. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA 76(14 Supplement), 2016. e-Pub 2016.
40. Morris V, Mahvash A, Vence L, Blando J, Wolff RA, Ohinata A, Ohaji C, Allison J, Sharma P, Eng C. NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA 76(14 Supplement), 2016. e-Pub 2016.
41. Subudhi SK, Aparicio A, Gao J, Zurita-Saavedra A, Araujo JC, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA 76(14 Supplement), 2016. e-Pub 2016.
42. Daver N, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Kornblau S, Konopleva M, Andreeff M, Borthakur G, Jain N, Wierda W, Verstovsek S, Ruvolo P, Kadia T, Matthews J, Flores W, Yang H, Bueso-Ramos C, Somani N, Blando J, Allison J, Kantarjian H, Sharma P. Defining the immune checkpoint landscape of acute myeloid leukemia (AML). Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA 76(14 Supplement), 2016. e-Pub 2016.
43. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, C-J W, Vence LM, Logothetis C, Futreal A, Allison JP, Sharma P. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). Proceedings of the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, IL, 2016. e-Pub 2016.
44. Reilley M, Blando JM, Katkhuda R, Menter D, Sharma P, Allison JP, Kopetz S, Maru DM, Overman MJ. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver mastectomy specimens: implications for immune targeting of proficient mismatch repair CRC. Proceedings of the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, IL, 2016. e-Pub 2016.
45. Reilley M, Bailey AM, Subbiah V, Janku F, Naing A, Falchook GS, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Lim J, Bean SA, Bass A, Montes S, Vence LM, Sharma P, Allison JP, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Proceedings of the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, IL, 2016. e-Pub 2016.
46. Sharma N, Allison J. Fc gamma receptor IV mediated depletion of tumor infiltrating regulatory T cells by anti-CTLA-4 antibody is promoted by TLR1/2 agonist and hence its efficacy in combination treatment of melanoma. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD, 2016. e-Pub 2016.
47. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Juliana L, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Allison J, Kantarjian HM, Sharma P. Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA 18(2900), 2016. e-Pub 2016.
48. Jain N, Basu S, Thakral B, Burger J, Thompson PA, Ferrajoli A, Estrov Z, Bueso-Ramos CE, Stingo F, Jr BR, Daver N, Kadia TM, Matthews J, Flores W, Somani N, Blando J, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Defining the immune checkpoint landscape in the bone marrow and peripheral blood of patients with chronic lymphocytic leukemia (CLL). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA 128(2012), 2016. e-Pub 2016.
49. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O’Brien SM, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Nivolumab combined with ibrutinib for CLL and richter transformation: a phase II trial. 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA 128(59), 2016. e-Pub 2016.
50. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O’Brien SM, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Nivolumab combined with ibrutinib for CLL and richter transformation: a phase II trial. 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA 128(59), 2016. e-Pub 2016.
51. Daver N, Garcia-Manero G, Basu S, Cortes J, Ravandi F, Jabbour EJ, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Borthakur G, Pemmaraju N, Bueso-Ramos CE, Lopez JH, Blando J, Allison J, Kantarjian HM, Sharma P. Phase IB/II study of lirilumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA 128(1641), 2016. e-Pub 2016.
52. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, Hidalgo Lopez JE, Allison J, Kantarjianand HM, Sharma P. Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA 128(763), 2016. e-Pub 2016.
53. Anderson C, Tang C, Schoenhals J, Tsouko E, Heymach J, de Groot P, Chang J, Hess KR, Diab A, Sharma P, Allison J, Naing A, Hong D, Welsh J. Neutrophil count predicts survival in patients on ipilimumab with radiation. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD, 2016. e-Pub 2016.
54. Wei S, Allison J. Deep profiling of tumor infiltrating immune subsets by mass cytometry. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD, 2016. e-Pub 2016.
55. Allison J. Immune checkpoint blockade in cancer therapy: new insights, opportunities, and prospects for cures. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston, MA 5(3 Supplement), 2016. e-Pub 2016.
56. Skoulidis F, Byers L, Diao L, Papadimitrakopoulou V, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan JH, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, K-K W, Zhang J, Sharma P, Mills GM, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba I, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, PA 75(15 Supplement), 2015. e-Pub 2015.
57. Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, Sacchini V, Maybody M, Neville D, Robins H, Patil S, Wolchok J, Hudis C, Norton L, Allison J, Sharma P, McArthur H. Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts). Thirty-Fifth Annual Cancer Therapy & Research Center (CTRC) American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium, San Antonio, TX 75(9 Supplement), 2015. e-Pub 2015.
58. Subudhi SK, Aparicio A, Gao J, Zurita A, John A, Logothetis C, Rao B, Vence L, Allison J, Emerson RO, Yusko E, Vignali M, Robins H, Sun JJ, Sharma P. Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer. 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015), National Harbor, MD, 2015. e-Pub 2015.
59. Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies M, yee C, W-J H, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM). 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015), National Harbor, MD, 2015. e-Pub 2015.
60. Page DB, Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Saccini V, Morrow M, Brogi E, Morris EA, Patil S, Robins H, Wolchok JD, Hudis CA, Norton L, Allison JP, McArthur HL. Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). Breast Cancer Symposium, San Francisco, CA, 2014. e-Pub 2014.
61. Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, Wolchok JD, Hudis CA, Norton L, Allison JP, McArthur HL. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). Proceedings of the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago, IL, 2014. e-Pub 2014.
62. Zamarin D, Holmgaard RB, Subudhi SK, J-S P, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Proceedings of the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago, IL, 2014. e-Pub 2014.
63. Diab A, Solomon SB, Comstock C, Maybody M, Sacchini V, Durack J, Blum B, Yuan J, Patil S, Neville D, Sung J, Kotin A, Morris E, Brogi E, Morrow M, Wolchok J, Allison J, Hudis C, Norton L, McArthur H. A pilot study of pre-operative (pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (cryo) in women (pts) with early stage/resectable breast cancer (ESBC). Thirty-Sixth Annual Cancer Therapy & Research Center (CTRC) American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium, San Antonio, TX 73(24 Supplement), 2013. e-Pub 2013.
64. Diab A, Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Sung JS, Blum B, Neville DA, Kotin A, Yuan J, Patil S, Morris EA, Brogi E, Morrow M, Wolchok JD, Hudis C, Allison J, Norton L, McArthur HL. A pilot study of preoperative, single-dose ipilimumab (Ipi) and/or cryoablation (cryo) in women (pts) with early stage/resectable breast cancer (ESBC). Proceedings of the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, Chicago, IL, 2013. e-Pub 2013.
65. Subudhi SK, Montalvo-Ortiz W, Scher HI, Allison JP. Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer. Genitourinary Cancers Symposium, Orlando, FL, 2013. e-Pub 2013.
66. Diab A, McArthur HL, Solomon S, Comstock C, Maybody M, Sacchini V, Durack J, Gucalp A, Yuan J, Patil S, Thorne A, Sung J, Kotin A, Morris E, Brogi E, Morrow M, Wolchok J, Allison J, Hudis C, Norton L. A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy. Thirty-Fifth Annual Cancer Therapy & Research Center (CTRC) American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium, San Antonio, TX 72(24 Supplement), 2012. e-Pub 2012.
67. Ariyan CE, Quezada S, Corse E, Montalvo W, Allison J. Improved survival with gemcitabine and CTLA-4 blockade in a murine model of prostate cancer. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL 71(8 Supplement), 2011. e-Pub 2011.
68. Sharma P, Kamat A, Tang DN, Chen H, Fu T, Sun J, Troncoso P, Yuan J, Wolchok J, Quezada S, Logothetis C, Allison J. Assessing immunologic impact of anti-CTLA-4 therapy on a pre-surgical clinical trial. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR), Denver, CO 69(9 Supplement), 2009. e-Pub 2009.
69. Yuan J, Ku G, Gallardo H, Orlandi F, Manukian G, Rasalan T, Li H, Xu Y, Vyas S, Mu Z, Simpronio J, Chapman P, Panageas K, Terzulli S, Allison J, Houghton A, Wolchok J. Safety and immunogenicity of gp100 DNA vaccines in patients with melanoma. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR), Denver, CO 69(9 Supplement), 2009. e-Pub 2009.
70. Curran M, Allison J. Cellular vaccines expressing Flt3-ligand synergize with CTLA-4 blockade to reject established tumors. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, CA 68(9 Supplement), 2008. e-Pub 2008.
71. Simmons AD, Moskalenko M, Creson J, Yi S, Allison JP, Fang J, Jooss K. Local secretion of anti-CTLA4 antibody from a GM-CSF-secreting tumor cell vaccine enhances vaccine efficacy. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC 66(8 Supplement), 2006. e-Pub 2006.
72. Demaria S, Kawashima N, Devitt ML, Babb JS, Allison JP, Formenti SC. Combination of local radiation with targeted immunomodulation improves systemic tumor control. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL 64(7 Supplement), 2004. e-Pub 2004.

Book Chapters

1. Allison, JP, Hodi, FS, Saenger, Y, Wolchok, JD. Immune modulators in the treatment of patients with melanoma, 775-792, 2024.
2. Subudhi SK, Scher HI, Allison JP. CTLA-4 inhibitors in castration-resistant prostate cancer. In: Targeted Therapies for Castration-Resistant Prostate Cancer. Future Medicine, 92-102, 2011.
3. Peggs KS, Quezada SA, Allison JP. Checkpoint blockade and combinatorial immunotherapies. In: General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology. Springer, The Netherlands, 363-90, 2007.
4. Allison JP. Modulation of the inhibitory effects of CTLA-4 in the enhancement of immunologic responses against cancer. In: Progress in Oncology. Sudbury, Massachusetts: Jones & Bartlett, 23-35, 2002.
5. Allison JP, Hurwitz AA, van Elsas A, Kwon E, Sullivan T, Foster B, Greenberg N. CTLA-4 blockade in tumor immunotherapy. In: Principles and Practice of the Biologic Therapy of Cancer. 3rd. Philadelphia: Lippincott Williams & Wilkins, 890-5, 2000.
6. Chambers CA, Allison JP. CTLA-4 – The costimulatory molecule that doesn’t: regulation of T-cell responses by inhibition. In: Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor Laboratory, 303-12, 1999.
7. Hurwitz AA, van Elsas A, Leach DR, Ziskin J, Villasenor J, Truong T, Allison JP. Manipulation of T cell activation to generate antitumor CTLs. In: Cytotoxic Cells: Basic Mechanisms and Medical Applications. Philadelphia: Lippincott Williams & Wilkins, 385-93, 1999.
8. Hurwitz AA, Leach DR, van Elsas A, Townsend SE, Allison JP. Manipulation of T cell activation in the anti-tumor immune response. In: The Biology of Tumors. New York: Plenum Press, 213-9, 1998.
9. Krummel M, Allison JP. B7-mediated co-stimulation of T cells: CTLA-4 can deliver inhibitory signals. In: Genetic Models of Immune and Inflammatory Diseases. New York: Springer-Verlag, 138-46, 1996.
10. Allison JP, Asarnow DM, Bonyhadi M, Carbone A, Havran WL, Nandi D, Noble J. Gamma delta-T cells in murine epithelia: origin, repertoire, and function. In: Adv Exp Med Biol. 3rd. New York: Plenum Press, 63, 1991.
11. Allison JP, Havran WL. The immunobiology of T cells with invariant delt gamma antigen receptors. In: Annual Review of Immunology. Palo Alto: Annual Reviews Inc, 679-705, 1991.
12. Havran WL, Allison JP. Fetal thymic origin of epithelial gamma delta T cells. In: Cellular Immunity and the Immunotherapy of Cancer, UCLA Symposia on Molecular and Cellular Biology, New Series. New York: Wiley-Liss, 23-30, 1990.
13. Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. . A role for CTLA-4 mediated inhibitory signals in peripheral T cell tolerance?. In: Novartis Foundation Symposium 215, Immunological Tolerance. Hoboken: John & Sons, 1988.
14. Allison JP, Havran WL, Poenie M, Kimura J, DeGraffenreid L, Ajami S, Duwe G, Weiss A, Tsien R. Expression and function of CD3 on murine thymocytes. In: UCLA Symposia on Molecular and Cellular Biology, New Series. New York: Alan R. Liss, Inc, 33-45, 1988.
15. Allison JP, Parham P. Evolution of the T cell antigen receptor. In: Evolution and Vertebrate Immunity. Austin: University of Texas Press, 213-24, 1987.
16. McIntyre BW, Lanier LL, Allison JP. The murine T cell receptor. In: Mitogen Specific Receptors and Factors. Boca Raton: CRC Press, Inc, 66-75, 1986.
17. Allison JP, McIntyre BW, Cheung FCY, Lanier LL. Molecular characterization of the murine T cell antigen receptor. In: Regulation of the Immune System, UCLA Symposia on Molecular and Cellular Biology. New York: Alan R. Liss, Inc, 1984.
18. Marrack P, Kubo R, Haskins K, Hannum C, White J, Pigeon M, Endres R, Shimonkevitz R, McIntyre B, Allison JP, Trowbridge I, Kappler J. T Cell hybridomas' use in studying T cell receptors for antigen plus MHC. In: Progress in Immunology V. New York: Academic Press, 735-54, 1983.
19. Allison JP, McIntyre BW, Irvin J, Bloch D, Kitto GB. Monoclonal antibody to tumor specific epitope to murine lymphoma cells: Use in characterization of antigen and in immunotherapy. In: Hybridomas and Cellular Immortality. New York: Plenum Publishing Company, 201-20, 1983.
20. Hixson DC, Ponce MDL, McEntire D, Chesner J, Lund JA, Allison JP, Jr WE. Identification of a liver glycoprotein which is present on both hepatocytes and extracellular biomatrix. 34th Falk Symposium. In: Structural Carbohydrates in the Liver, 577-85, 1983.
21. Allison JP, McIntyre BW. The murine T cell antigen receptor. In: Progress in Immunology V. New York: Academic Press, 755-62, 1983.
22. Hixson DC, Allison JP, Chesner JE, Leger MJ, Ridge LL, Thomas MW, Jr WE. Variation in the expression and structure of a subset of normal bile canalicular glycoproteins on transplantable hepatocellular carcinomas. In: Membranes in Tumour Growth. Amsterdam: Elsevier Biomedical Press, 19-27, 1982.
23. Allison JP, Hixson DC, Lund JN, Chesner JE, Ridge LL, Leger MJ, McEntire KD, Jr WE. Monoclonal antibodies as probes of surface antigenic alteration during experimental hepatocarcinogenesis in the rats. In: Membranes in Tumour Growth. Amsterdam: Elsevier Biomedical Press, 599-606, 1982.
24. Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Histocompatibility and tumor-associated antigens in serum. In: Handbook of Cancer Immunology. New York: Garland STPM Publishing Company, 79-104, 1981.
25. Walker LE, Allison JP, Silver J, Pellegrino MA, Reisfeld RA, Ferrone S. Is serological polymorphism of human DR antigens determined by structural differences in the smaller (beta) chain?. In: Cell Biology and Immunology of Leukocyte Function. New York: Academic Press, 271-6, 1979.
26. Belvedere M, Allison JP, Reisfeld R, Pellegrino M, Ferrone S. Serum HLA antigens: serological and immunogenic properties. In: HLA Antigens in Clinical Medical and Biology. New York: Garland Press, 19-27, 1979.
27. Jr WE, Starling JJ, Davis EM, Hixson DC, Allison JP. Plasma membrane alterations during carcinogenesis. In: Carcinogens: Identification and Mechanisms of Action. New York: Raven Press, 381-98, 1979.
28. Ferrone S, Pellegrino M, Allison JP. Rabbit complement in the cytotoxic test with antibody-coated nucleated cells: properties and role of human antigens reactive with rabbit natural antibodies. In: HLA Antigens in Clinical Medical and Biology. New York: Garland Press, 28-36, 1979.
29. Ferrone S, Pellegrino MA, Belvedere M, Reisfeld RA, Curry R, Allison JP. Human B cell antigens: biological and immunogenic properties. In: Protides of Biological Fluids, 25th Colloquium 1977. Oxford: Pergamon Press, 645-52, 1978.

Patents

1. SPAS-1 Cancer Antigen. Patent Number: US20020150588 A1.
2. Allison JP, Leach DR, Krummel ME. Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling. Patent Number: US7229628 B1.
3. Allison J, Curran M. Methods and Compositions for Localized Secretion of Anti-CTLA-4 Antibodies. Patent Number: US 9,868,961 B2.
4. Compositions and Methods for Modulating Lymphocyte Activity. Patent Number: US20040175380 A1.
5. Allison JP, Fasso M, Shastri N. Diagnosis of Prostate Cancer with SPAS-1 Cancer Antigen. Patent Number: US7704701 B2.
6. Zang X, Allison JP. Antibodies to Human B7X for Treatment of Metastatic Cancer. Patent Number: US9447186 B2.
7. Simmons A, Jooss K, Allison J. Cancer Immunotherapy Compositions and Methods of Use. Patent Number: US7919079 B2.
8. Allison JP, Leach DR, Krummel MF. Blockade of Lymphocyte Down-Regulation Associated with CTLA-4 Signaling. Patent Number: US5855887 A.
9. Allison JP, Elsas A, Hurwitz A. Stimulation of T Cells Against Self Antigens Using CTLA-4 Blocking Agents. Patent Number: US20060034844 A1.
10. Allison J, Sharma P, Quezada SA, Fu T. Combination Immunotherapy for the Treatment of Cancer. Patent Number: US9375475 B2.
11. Palese P, Garcia-Sastre A, Zamarin D, Allison J, Wolchok JD. Newcastle Disease Viruses and Uses Thereof. Patent Number: US20160015760 A1.
12. Allison JP, Leach DR, Krummel MF. Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling. Patent Number: US6051227 A.
13. Allison JP, Leach DR, Krummel MF. Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling. Patent Number: US5811097 A.